EP3184102A1 — Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
Assigned to Hexal AG · Expires 2017-06-28 · 9y expired
What this patent protects
The present invention relates to a solid oral pharmaceutical composition comprising an inert core comprising, preferably consisting of, at least one acidic reacting compound, and a coating comprising vortioxetine hydrobromide and at least one pharmaceutically acceptable polymer a…
USPTO Abstract
The present invention relates to a solid oral pharmaceutical composition comprising an inert core comprising, preferably consisting of, at least one acidic reacting compound, and a coating comprising vortioxetine hydrobromide and at least one pharmaceutically acceptable polymer and a method for enhancing the solubility and bioavailability of vortioxetine hydrobromide.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.